A service coverage index has not too long ago been proposed to watch progress in direction of universal health coverage (UHC), and baseline outcomes for 2015 can be found. However, proof on equity in that progress is scarce. The service coverage index didn’t contemplate services for neglected tropical diseases (NTDs), a gaggle of preventable diseases outlined by WHO member states on the premise of the disproportionate burden they place on their poorest, remotest, and in any other case most marginalised communities. Because of the much-needed equity lens that it may present, NTD service coverage shouldn’t be neglected in efforts to watch UHC progress.
We developed an index centered on coverage of services for NTDs, comparable in strategies to the UHC service coverage index. On the premise of data availability, we centered on preventive chemotherapy, which was not too long ago included in the highest-priority bundle of essential UHC interventions. We used data reported to WHO since 2008 for the five NTDs amenable to preventive chemotherapy (lymphatic filariasis, onchocerciasis, schistosomiasis, soil-transmitted helminthiases, and trachoma) to develop an NTD service coverage index primarily based on the geometric imply of coverage charges for particular person NTD services with recurrently reported data. We then in contrast this NTD service coverage index with the UHC service coverage index.
A excessive UHC index worth and a low NTD index worth counsel {that a} nation may not be adequately prioritising interventions for the poor. We measured Spearman rank-order correlation (ρ) of the NTD service coverage index with revenue inequality, as measured by the Gini coefficient (vary of 0-1), the place values of the Gini coefficient near 1 point out greater revenue inequality, and a destructive correlation was proof of socioeconomic boundaries to health service coverage for people who find themselves least effectively off.
At least 123 countries can monitor NTD service coverage by use of a easy index. The median nationwide NTD index was 32 in 2016, an enhance from 3 in 2012, and from 0 in 2008. In 2015, the NTD index was decrease than the UHC index in 81 of the 113 countries for which each NTD and UHC indices can be found, by as much as 80 factors. The NTD index was negatively however weakly correlated with revenue inequality; this correlation was strongest in the African Region (ρ=-0·46 in 2008, ρ=-0·32 in 2015), suggesting that high-income inequality, though related with low coverage of services concentrating on the poor, doesn’t preclude the extension of that coverage.
The NTD index can be utilized to measure equity in progress in direction of UHC. A broader NTD index together with services for different NTDs may very well be developed at regional and nation ranges. Comparing the NTD and UHC service coverage indices reveals that some countries which might be performing effectively by the measure of the UHC service coverage index nonetheless have work to do in prioritising services for their poorest and in any other case most marginalised communities. Our outcomes provide hope that socioeconomic boundaries to health service coverage will be overcome. Village chiefs have been briefed concerning the exercise. The educated crew visited the villages and colleges in the district of Lalo in Benin.
Integrated method in the management and administration of pores and skin neglected tropical diseases in Lalo, Benin.
Neglected Tropical Diseases (NTDs) are a gaggle of a number of communicable diseases prevalent in the tropical and subtropical areas. The co-endemicity of these diseases, the similarity of the scientific indicators, and wish to maximise restricted monetary and human sources have necessitated implementation of built-in method. Our research goals to share the teachings of this built-in method in the combat towards Buruli ulcer (BU), leprosy and yaws in a rural district in Benin. It is a cross-sectional research utilizing a single set of actions data performed from May 2016 to December 2016. Health employees and neighborhood health volunteers concerned in this research have been educated on built-in method of the Buruli ulcer, leprosy and yaws.
After the training and consciousness elevating periods, all individuals with a pores and skin lesion who offered voluntarily to the crew have been rigorously examined in a well-lit space which revered their privateness. Suspected instances have been examined as wanted. The socio-demographic data and the traits of the lesions have been collected utilizing a type. A descriptive analysis of the epidemiological, scientific and laboratory variables of the instances was made utilizing Excel 2013 and SPSS model 22.00. In the research interval, 1106 folks have been examined. The median (IQR) age of these examined was 11 (8; 27) years. Of 34 (3.1%) suspected BU instances, 15 (1.4%) have been confirmed by PCR.
Towards a science of international health supply: A socio-anthropological framework to enhance the effectiveness of neglected tropical illness interventions.
The framework was developed inductively by comparatively analyzing three speedy ethnographic research undertaken in Eastern Africa (2010-2013) on three completely different large-scale NTD interventions: rabies elimination in Tanzania, sleeping illness management in Uganda and the prevention of parasitic worms in Zambia. The framework contains five “intervention domains” the place the effectiveness of these interventions was negotiated and decided on the native stage.
This includes: 1) the terrain of intervention (together with seasonality and geographical variability); 2) neighborhood company (together with native data, danger perceptions, behaviors, management and social strain); 3) the methods and incentives of discipline workers (abilities, motivations, capabilities and help); 4) the socio-materiality of expertise (traits of intervention instruments and the adoption course of itself); and 5) the governance of interventions (coverage narratives, obtainable experience, forms, politics and the utilization of data). The paper illustrates the significance of every of these domains by drawing on the case research analysis, presenting classes learnt and sensible suggestions for how such insights may enhance intervention supply.
Pig Thrombopoietin (THPO) ELISA Kit |
abx511938-96tests |
Abbexa |
96 tests |
EUR 904.8 |
|
Rat Thrombopoietin (THPO) ELISA Kit |
20-abx156148 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
|
- 10 × 96 tests
- 5 × 96 tests
- 96 tests
|
|
Rat Thrombopoietin (THPO) ELISA Kit |
abx256183-1096tests |
Abbexa |
10 × 96 tests |
Ask for price |
Rat Thrombopoietin (THPO) ELISA Kit |
abx256183-596tests |
Abbexa |
5 × 96 tests |
Ask for price |
Rat Thrombopoietin (THPO) ELISA Kit |
abx156148-100g |
Abbexa |
100 µg |
EUR 6075 |
Rat Thrombopoietin (THPO) ELISA Kit |
abx156148-10g |
Abbexa |
10 µg |
EUR 675 |
Rat Thrombopoietin (THPO) ELISA Kit |
abx156148-50g |
Abbexa |
50 µg |
EUR 3212.5 |
Human Thrombopoietin (THPO) ELISA Kit |
20-abx153282 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
|
- 10 × 96 tests
- 5 × 96 tests
- 96 tests
|
|
Mouse Thrombopoietin (THPO) ELISA Kit |
abx050222-96tests |
Abbexa |
96 tests |
EUR 801.6 |
|
Mouse Thrombopoietin (THPO) ELISA Kit |
abx254573-96tests |
Abbexa |
96 tests |
EUR 782.4 |
|
Human Thrombopoietin (THPO) ELISA Kit |
abx253423-96tests |
Abbexa |
96 tests |
EUR 764.4 |
|
Human Thrombopoietin (THPO) ELISA Kit |
abx574586-96tests |
Abbexa |
96 tests |
EUR 877.2 |
|
Mouse Thrombopoietin (THPO) ELISA Kit |
abx576171-96tests |
Abbexa |
96 tests |
EUR 782.4 |
|
Mouse Thrombopoietin (THPO) ELISA Kit |
20-abx154753 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
|
- 10 × 96 tests
- 5 × 96 tests
- 96 tests
|
|
Human Thrombopoietin (THPO) ELISA Kit |
abx350302-96tests |
Abbexa |
96 tests |
EUR 877.2 |
|
Mouse Thrombopoietin (THPO) ELISA Kit |
abx050222-1mg |
Abbexa |
1 mg |
EUR 481.25 |
Mouse Thrombopoietin (THPO) ELISA Kit |
abx050222-5mg |
Abbexa |
5 mg |
Ask for price |
Rabbit Thrombopoietin (THPO) ELISA Kit |
abx362338-96tests |
Abbexa |
96 tests |
EUR 990 |
|
Monkey Thrombopoietin (THPO) ELISA Kit |
abx360299-96tests |
Abbexa |
96 tests |
EUR 904.8 |
|
Canine Thrombopoietin (THPO) ELISA Kit |
AE17354DO-48T |
Abebio |
48T |
EUR 230 |
|
Description: Canine (Canis familiaris; Dog) |
Canine Thrombopoietin (THPO) ELISA Kit |
AE17354DO-96T |
Abebio |
96T |
EUR 680 |
|
Description: Canine (Canis familiaris; Dog) |
Canine Thrombopoietin (THPO) ELISA Kit |
RK06278 |
Abclonal |
96T |
EUR 280 |
Chicken Thrombopoietin (THPO) ELISA Kit |
abx574585-96tests |
Abbexa |
96 tests |
EUR 904.8 |
|
Guinea pig Thrombopoietin (THPO) ELISA Kit |
abx358167-96tests |
Abbexa |
96 tests |
EUR 904.8 |
|
Dog THPO/ Thrombopoietin ELISA Kit |
E0103Do |
Sunlong |
1 Kit |
EUR 630 |
|
Description: TPO,C-MPL ligand,Megakaryocyte colony-stimulating factor,Megakaryocyte growth and development factor,ML,MGDF |
Rat Thpo/ Thrombopoietin ELISA Kit |
E0975Ra |
Sunlong |
1 Kit |
EUR 557 |
|
Dog THPO / Thrombopoietin ELISA Kit |
E0135d |
EIAab |
96T |
EUR 900 |
Pig THPO / Thrombopoietin ELISA Kit |
E0135p |
EIAab |
96T |
EUR 900 |
Rat Thpo / Thrombopoietin ELISA Kit |
E0135r |
EIAab |
96T |
EUR 796 |
Mouse Thpo/ Thrombopoietin ELISA Kit |
E1469Mo |
Sunlong |
1 Kit |
EUR 543 |
|
Description: C-mpl ligand,Megakaryocyte colony-stimulating factor,Megakaryocyte growth and development factor,Myeloproliferative leukemia virus oncogene ligand,ML,MGDF |
Human THPO/ Thrombopoietin ELISA Kit |
E2494Hu |
Sunlong |
1 Kit |
EUR 515 |
|
Description: MGDF,C-mpl ligand,Megakaryocyte colony-stimulating factor,Megakaryocyte growth and development factor,Myeloproliferative leukemia virus oncogene ligand,ML,MGDF |
Human THPO / Thrombopoietin ELISA Kit |
E0135h |
EIAab |
96T |
EUR 536 |
Mouse Thpo / Thrombopoietin ELISA Kit |
E0135m |
EIAab |
96T |
EUR 776 |
Rat Thrombopoietin (Thpo) |
1-CSB-RP076444r |
Cusabio |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 100ug
- 10ug
- 1MG
- 200ug
- 500ug
- 50ug
|
|
Description: Recombinant Rat Thrombopoietin(Thpo),partial expressed in E.coli |
Low Sample Volume Human Thrombopoietin (THPO) ELISA Kit |
abx052334-100g |
Abbexa |
100 µg |
EUR 6637.5 |
Low Sample Volume Human Thrombopoietin (THPO) ELISA Kit |
abx052334-10g |
Abbexa |
10 µg |
EUR 737.5 |
Low Sample Volume Human Thrombopoietin (THPO) ELISA Kit |
abx052334-50g |
Abbexa |
50 µg |
EUR 3512.5 |
Rat Thrombopoietin (THPO) CLIA Kit |
abx197777-96tests |
Abbexa |
96 tests |
EUR 990 |
|
Cow Thrombopoietin (THPO) CLIA Kit |
20-abx491111 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
|
- 10 × 96 tests
- 5 × 96 tests
- 96 tests
|
|
Dog Thrombopoietin (THPO) CLIA Kit |
20-abx491112 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
|
- 10 × 96 tests
- 5 × 96 tests
- 96 tests
|
|
Rat Thrombopoietin (THPO) CLIA Kit |
20-abx491114 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
|
- 10 × 96 tests
- 5 × 96 tests
- 96 tests
|
|
Rat Thrombopoietin (THPO) CLIA Kit |
abx197777-100l |
Abbexa |
100 µl |
Ask for price |
Rat Thrombopoietin (THPO) CLIA Kit |
abx197777-50l |
Abbexa |
50 µl |
EUR 618.75 |
Thrombopoietin (THPO) Antibody |
20-abx128496 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Thrombopoietin (THPO) Antibody |
20-abx128675 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Thrombopoietin (THPO) Antibody |
20-abx130328 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Thrombopoietin (THPO) Antibody |
abx011134-100ug |
Abbexa |
100 ug |
EUR 493.2 |
|
Thrombopoietin (THPO) Antibody |
20-abx008636 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
|
|
|
Thrombopoietin (THPO) Antibody |
20-abx001508 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 100 ul
- 200 ul
- 20 ul
- 50 ul
|
|
Thrombopoietin (THPO) Antibody |
20-abx174762 |
Abbexa |
-
Ask for price
-
Ask for price
|
|
|
Thrombopoietin (THPO) Antibody |
20-abx174763 |
Abbexa |
-
Ask for price
-
Ask for price
|
|
|
Thrombopoietin (THPO) Antibody |
20-abx174764 |
Abbexa |
-
Ask for price
-
Ask for price
|
|
|
Thrombopoietin (THPO) Antibody |
20-abx174765 |
Abbexa |
-
Ask for price
-
Ask for price
|
|
|
Thrombopoietin (THPO) Antibody |
20-abx178565 |
Abbexa |
-
Ask for price
-
Ask for price
|
|
|
Thrombopoietin (THPO) Antibody |
20-abx178566 |
Abbexa |
-
Ask for price
-
Ask for price
|
|
|
Thrombopoietin (THPO) Antibody |
20-abx178567 |
Abbexa |
-
Ask for price
-
Ask for price
|
|
|
Thrombopoietin (THPO) Antibody |
20-abx178568 |
Abbexa |
-
Ask for price
-
Ask for price
|
|
|
Thrombopoietin (THPO) Antibody |
20-abx178569 |
Abbexa |
-
Ask for price
-
Ask for price
|
|
|
Thrombopoietin (THPO) Antibody |
20-abx178570 |
Abbexa |
-
Ask for price
-
Ask for price
|
|
|
Thrombopoietin (THPO) Antibody |
20-abx323791 |
Abbexa |
-
Ask for price
-
Ask for price
|
|
|
Thrombopoietin (Thpo) Antibody |
20-abx319766 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
Thrombopoietin (THPO) Antibody |
abx128496-100l |
Abbexa |
100 µl |
EUR 250 |
Thrombopoietin (THPO) Antibody |
abx128496-1ml |
Abbexa |
1 ml |
EUR 675 |
Thrombopoietin (THPO) Antibody |
abx128496-200l |
Abbexa |
200 µl |
EUR 312.5 |
Thrombopoietin (THPO) Antibody |
abx128675-100l |
Abbexa |
100 µl |
EUR 250 |
Thrombopoietin (THPO) Antibody |
abx128675-1ml |
Abbexa |
1 ml |
EUR 675 |
Thrombopoietin (THPO) Antibody |
abx128675-200l |
Abbexa |
200 µl |
EUR 312.5 |
Thrombopoietin (THPO) Antibody |
abx174762-100l |
Abbexa |
100 µl |
EUR 712.5 |
Thrombopoietin (THPO) Antibody |
abx174762-1ml |
Abbexa |
1 ml |
Ask for price |
Thrombopoietin (THPO) Antibody |
abx174762-200l |
Abbexa |
200 µl |
Ask for price |
Thrombopoietin (THPO) Antibody |
abx174763-100l |
Abbexa |
100 µl |
EUR 775 |
Thrombopoietin (THPO) Antibody |
abx174763-1ml |
Abbexa |
1 ml |
Ask for price |
Thrombopoietin (THPO) Antibody |
abx174763-200l |
Abbexa |
200 µl |
Ask for price |
Thrombopoietin (THPO) Antibody |
abx130328-100l |
Abbexa |
100 µl |
EUR 262.5 |
Thrombopoietin (THPO) Antibody |
abx130328-1ml |
Abbexa |
1 ml |
EUR 725 |
Thrombopoietin (THPO) Antibody |
abx130328-200l |
Abbexa |
200 µl |
EUR 337.5 |
Thrombopoietin (THPO) Antibody |
abx178565-96tests |
Abbexa |
96 tests |
EUR 687.5 |
Thrombopoietin (THPO) Antibody |
abx178567-96tests |
Abbexa |
96 tests |
EUR 262.5 |
Thrombopoietin (THPO) Antibody |
abx323791-100g |
Abbexa |
100 µg |
EUR 250 |
Thrombopoietin (THPO) Antibody |
abx323791-50g |
Abbexa |
50 µg |
EUR 187.5 |
Thrombopoietin (Thpo) Antibody |
abx319766-100l |
Abbexa |
100 µl |
EUR 250 |
Thrombopoietin (Thpo) Antibody |
abx319766-50l |
Abbexa |
50 µl |
EUR 162.5 |
Thrombopoietin (THPO) Antibody |
abx011134-100g |
Abbexa |
100 µg |
Ask for price |
Thrombopoietin (THPO) Antibody |
abx011134-10g |
Abbexa |
10 µg |
EUR 362.5 |
Thrombopoietin (THPO) Antibody |
abx011134-200g |
Abbexa |
200 µg |
Ask for price |
Thrombopoietin (THPO) Antibody |
abx001508-100l |
Abbexa |
100 µl |
EUR 400 |
Thrombopoietin (THPO) Antibody |
abx001508-20l |
Abbexa |
20 µl |
EUR 175 |
Thrombopoietin (THPO) Antibody |
abx001508-50l |
Abbexa |
50 µl |
EUR 275 |
Human Thrombopoietin (THPO) CLIA Kit |
20-abx190081 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
|
- 10 × 96 tests
- 5 × 96 tests
- 96 tests
|
|
Human Thrombopoietin (THPO) CLIA Kit |
abx197775-96tests |
Abbexa |
96 tests |
EUR 990 |
|
Mouse Thrombopoietin (THPO) CLIA Kit |
abx197776-96tests |
Abbexa |
96 tests |
EUR 990 |
|
Mouse Thrombopoietin (THPO) CLIA Kit |
20-abx491113 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
|
- 10 × 96 tests
- 5 × 96 tests
- 96 tests
|
|
Human Thrombopoietin (THPO) CLIA Kit |
abx197775-100l |
Abbexa |
100 µl |
Ask for price |
Human Thrombopoietin (THPO) CLIA Kit |
abx197775-50l |
Abbexa |
50 µl |
EUR 618.75 |
Mouse Thrombopoietin (THPO) CLIA Kit |
abx197776-100l |
Abbexa |
100 µl |
Ask for price |
Mouse Thrombopoietin (THPO) CLIA Kit |
abx197776-50l |
Abbexa |
50 µl |
EUR 618.75 |
Thrombopoietin Antibody (THPO) |
F50509-0.08ML |
NSJ Bioreagents |
0.08 ml |
EUR 140.25 |
|
Description: Megakaryocytopoiesis is the cellular development process that leads to platelet production. THPO is a humoral growth factor that is necessary for megakaryocyte proliferation and maturation, as well as for thrombopoiesis. It is the ligand for MLP/C_MPL, the product of myeloproliferative leukemia virus oncogene. |
Thrombopoietin Antibody (THPO) |
F50509-0.4ML |
NSJ Bioreagents |
0.4 ml |
EUR 322.15 |
|
Description: Megakaryocytopoiesis is the cellular development process that leads to platelet production. THPO is a humoral growth factor that is necessary for megakaryocyte proliferation and maturation, as well as for thrombopoiesis. It is the ligand for MLP/C_MPL, the product of myeloproliferative leukemia virus oncogene. |
Thrombopoietin Antibody / THPO |
R32719 |
NSJ Bioreagents |
100ug |
EUR 356.15 |
|
Description: Thrombopoietin (THPO), also known as megakaryocyte growth and development factor (MGDF), is a protein that in humans is encoded by the THPO gene. Megakaryocytopoiesis is the cellular development process that leads to platelet production. The main functional protein encoded by this gene is a humoral growth factor that is necessary for megakaryocyte proliferation and maturation, as well as for thrombopoiesis. This protein is the ligand for MLP/C_MPL, the product of myeloproliferative leukemia virus oncogene. Mutations in this gene are the cause of thrombocythemia 1. Alternative promoter usage and differential splicing result in multiple transcript variants differing in the 5' UTR and/or coding region. Multiple AUG codons upstream of the main open reading frame (ORF) have been identified, and these upstream AUGs inhibit translation of the main ORF at different extent. |
Thrombopoietin Antibody / THPO |
R32570 |
NSJ Bioreagents |
100 ug |
EUR 356.15 |
|
Description: Thrombopoietin (THPO), also known as megakaryocyte growth and development factor (MGDF), is a protein that in humans is encoded by the THPO gene. Megakaryocytopoiesis is the cellular development process that leads to platelet production. The main functional protein encoded by this gene is a humoral growth factor that is necessary for megakaryocyte proliferation and maturation, as well as for thrombopoiesis. This protein is the ligand for MLP/C_MPL, the product of myeloproliferative leukemia virus oncogene. Mutations in this gene are the cause of thrombocythemia 1. Alternative promoter usage and differential splicing result in multiple transcript variants differing in the 5' UTR and/or coding region. Multiple AUG codons upstream of the main open reading frame (ORF) have been identified, and these upstream AUGs inhibit translation of the main ORF at different extent. |
Thrombopoietin Antibody / THPO |
RQ4662 |
NSJ Bioreagents |
100ug |
EUR 356.15 |
|
Description: Thrombopoietin (THPO), also known as megakaryocyte growth and development factor (MGDF), is a protein that in humans is encoded by the THPO gene. Megakaryocytopoiesis is the cellular development process that leads to platelet production. The main functional protein encoded by this gene is a humoral growth factor that is necessary for megakaryocyte proliferation and maturation, as well as for thrombopoiesis. This protein is the ligand for MLP/C_MPL, the product of myeloproliferative leukemia virus oncogene. Mutations in this gene are the cause of thrombocythemia 1. Alternative promoter usage and differential splicing result in multiple transcript variants differing in the 5' UTR and/or coding region. Multiple AUG codons upstream of the main open reading frame (ORF) have been identified, and these upstream AUGs inhibit translation of the main ORF at different extent. |
Thrombopoietin Antibody / THPO |
RQ4123 |
NSJ Bioreagents |
100 ug |
EUR 356.15 |
|
Description: Thrombopoietin (THPO), also known as megakaryocyte growth and development factor (MGDF), is a protein that in humans is encoded by the THPO gene. Megakaryocytopoiesis is the cellular development process that leads to platelet production. The main functional protein encoded by this gene is a humoral growth factor that is necessary for megakaryocyte proliferation and maturation, as well as for thrombopoiesis. This protein is the ligand for MLP/C_MPL, the product of myeloproliferative leukemia virus oncogene. Mutations in this gene are the cause of thrombocythemia 1. Alternative promoter usage and differential splicing result in multiple transcript variants differing in the 5' UTR and/or coding region. Multiple AUG codons upstream of the main open reading frame (ORF) have been identified, and these upstream AUGs inhibit translation of the main ORF at different extent. |
Rat Thrombopoietin (THPO) Protein |
20-abx167599 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Cow Thrombopoietin (THPO) Protein |
20-abx655220 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Pig Thrombopoietin (THPO) Protein |
20-abx655221 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Dog Thrombopoietin (THPO) Protein |
20-abx655223 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Rat Thrombopoietin (THPO) Protein |
abx167599-1ml |
Abbexa |
1 ml |
EUR 225 |
Cow Thrombopoietin (THPO) Protein |
abx655220-10g |
Abbexa |
10 µg |
EUR 2112.5 |
Cow Thrombopoietin (THPO) Protein |
abx655220-50g |
Abbexa |
50 µg |
EUR 5300 |
Pig Thrombopoietin (THPO) Protein |
abx655221-10g |
Abbexa |
10 µg |
EUR 375 |
Pig Thrombopoietin (THPO) Protein |
abx655221-50g |
Abbexa |
50 µg |
EUR 537.5 |
Dog Thrombopoietin (THPO) Protein |
abx655223-10g |
Abbexa |
10 µg |
EUR 437.5 |
Dog Thrombopoietin (THPO) Protein |
abx655223-50g |
Abbexa |
50 µg |
EUR 625 |
Thrombopoietin (Thpo) Antibody (HRP) |
20-abx319713 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
Thrombopoietin (Thpo) Antibody (HRP) |
abx319713-100l |
Abbexa |
100 µl |
EUR 250 |
Thrombopoietin (Thpo) Antibody (HRP) |
abx319713-50l |
Abbexa |
50 µl |
EUR 162.5 |
Mouse Thrombopoietin (THPO) Protein |
20-abx263587 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
|
|
|
Human Thrombopoietin (THPO) Protein |
20-abx262160 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
|
|
|
Human Thrombopoietin (THPO) Protein |
20-abx168087 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Human Thrombopoietin (THPO) Protein |
20-abx166502 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Thrombopoietin (Thpo) Antibody (FITC) |
20-abx319714 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
Mouse Thrombopoietin (THPO) Protein |
20-abx652078 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Human Thrombopoietin (THPO) Protein |
abx166502-100g |
Abbexa |
100 µg |
EUR 537.5 |
Human Thrombopoietin (THPO) Protein |
abx166502-10g |
Abbexa |
10 µg |
EUR 212.5 |
Human Thrombopoietin (THPO) Protein |
abx166502-50g |
Abbexa |
50 µg |
EUR 375 |
Human Thrombopoietin (THPO) Protein |
abx168087-100l |
Abbexa |
100 µl |
EUR 212.5 |
Human Thrombopoietin (THPO) Protein |
abx168087-1ml |
Abbexa |
1 ml |
EUR 537.5 |
Human Thrombopoietin (THPO) Protein |
abx168087-200l |
Abbexa |
200 µl |
EUR 375 |
Mouse Thrombopoietin (THPO) Protein |
abx263587-10mg |
Abbexa |
10 mg |
EUR 4950 |
To assist shut the hole between efficacy and effectiveness in NTD applications, it will be important that discipline workers: 1) generate significant data about contextual components; 2) use this information to tailor discipline methods; and three) create routine mechanisms to account for the dynamic course of of implementation itself. The framework offered right here provides a easy analytical software to strengthen these knowledge-to-action relationships present undertaking planning instruments, drawing on the insights of socio-anthropology.